Sign in

    Ronny Dvir

    Vice President and Equity Research Analyst at JPMorgan Chase & Co.

    Ronny Dvir is a Vice President and Equity Research Analyst at JPMorgan Chase & Co., specializing in coverage of the real estate and REIT sectors with in-depth analysis of companies such as Simon Property Group, Prologis, and Vornado Realty Trust. He has consistently delivered actionable investment insights, maintaining a strong performance record reflected by his positive ranking on analyst platforms and delivering above-industry average returns. Dvir began his career in financial analysis in the early 2010s, previously holding roles at smaller asset management firms before joining JPMorgan in 2018. He holds professional credentials including FINRA Series 7 and 63 licenses, underscoring his expertise and regulatory compliance in securities research.

    Ronny Dvir's questions to Vir Biotechnology (VIR) leadership

    Ronny Dvir's questions to Vir Biotechnology (VIR) leadership • Q1 2025

    Question

    Ronny Dvir, on behalf of Eric Joseph, asked how a recent clinical update on bulevirtide impacts VIR's strategic thinking around the potential for finite versus long-term chronic treatment for Hepatitis Delta Virus (HDV).

    Answer

    Mark Eisner (Executive) contrasted VIR's approach by emphasizing the high rates of complete viral suppression (64% at week 36) seen in the SOLSTICE study, compared to bulevirtide's 12% at week 48. He noted that the competitor's finite treatment data involves a higher, off-label dose. He reiterated that VIR is aiming for a potent, chronic viral suppressive regimen, supported by deep viral suppression and significant declines in hepatitis B surface antigen.

    Ask Fintool Equity Research AI